Earnings Results: Shares of Bausch up 4% after company gives rosier full-year guidance

Bausch Health Companies Inc., formerly known as Valeant Pharmaceuticals, raised its full-year outlook on Monday, after reporting first-quarter revenue that missed expectations.

Investors didn’t seem too bothered by the miss, focusing mostly on the company’s BHC, +6.23% rosier guidance. Shares shot up as much as 7% Monday morning after Bausch said it was now expecting full-year revenue to come in between $8.35 billion and $8.55 billion, up from its previous prediction of between $8.30 billion and $8.50 billion.

In case you missed it: CVS raises guidance for 2019 after earnings beat as Aetna boosts revenue

More in health-care earnings: UnitedHealth stock falls despite earnings beat, signaling investor jitters over ‘Medicare for All’

>>> Original Source <<<